CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-23
DOI
10.1038/s41591-023-02612-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
- (2023) Francesca Del Bufalo et al. NEW ENGLAND JOURNAL OF MEDICINE
- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
- (2022) Robbie G. Majzner et al. NATURE
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
- (2022) Changsong Qi et al. NATURE MEDICINE
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
- (2022) Vivek Narayan et al. NATURE MEDICINE
- CAR-T Cell Performance: How to Improve Their Persistence?
- (2022) Gina López-Cantillo et al. Frontiers in Immunology
- GPRC5D-Targeted CAR T Cells for Myeloma
- (2022) Sham Mailankody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
- (2022) Francesco Boccalatte et al. Cancers
- Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
- (2022) Christian L. Flugel et al. Nature Reviews Clinical Oncology
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)
- (2021) Huan Du et al. Molecular Medicine Reports
- Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis
- (2021) Chiyuan Zhang et al. Frontiers in Cell and Developmental Biology
- 421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT
- (2021) Mark Linch et al. Journal for ImmunoTherapy of Cancer
- An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
- (2020) Katharina Reinhard et al. SCIENCE
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
- (2020) Ugur Sahin et al. NATURE
- TARGETED TREATMENT APPROACHES IN REFRACTORY GERM CELL TUMORS
- (2019) Laura Galvez-Carvajal et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Abstract 1907: Claudin 6 is a carcinoembryonic antigen with cancer stem cell marker features
- (2018) Özlem Türeci et al. CANCER RESEARCH
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
- (2018) Alexandra G. Orlandini von Niessen et al. MOLECULAR THERAPY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial
- (2016) Sandra Heesch et al. CANCER RESEARCH
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care—Registry data from an outcomes research project of the German Testicular Cancer Study Group
- (2016) Christoph Seidel et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
- (2015) Christiane R. Stadler et al. OncoImmunology
- Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer
- (2014) Patrick Micke et al. INTERNATIONAL JOURNAL OF CANCER
- Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas
- (2012) Tetsuo Ushiku et al. HISTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started